Published in J Clin Oncol on May 04, 2009
Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA (2013) 5.71
Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. J Clin Oncol (2014) 4.75
Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer (2013) 4.46
Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol (2011) 2.96
Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab (2011) 2.93
Progress in molecular-based management of differentiated thyroid cancer. Lancet (2013) 2.44
Morphology predicts BRAF (V⁶⁰⁰E) mutation in papillary thyroid carcinoma: an interobserver reproducibility study. Virchows Arch (2014) 1.99
Prognostic utility of BRAF mutation in papillary thyroid cancer. Mol Cell Endocrinol (2009) 1.96
Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation. Thyroid (2013) 1.45
BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis. J Clin Endocrinol Metab (2012) 1.39
Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants. J Clin Endocrinol Metab (2015) 1.24
Late intervention with anti-BRAF(V600E) therapy induces tumor regression in an orthotopic mouse model of human anaplastic thyroid cancer. Endocrinology (2011) 1.13
BRAF V600E mutation and papillary thyroid cancer. JAMA (2013) 1.03
The utility of BRAF testing in the management of papillary thyroid cancer. Oncologist (2010) 1.03
RET/PTC Translocations and Clinico-Pathological Features in Human Papillary Thyroid Carcinoma. Front Endocrinol (Lausanne) (2012) 1.00
Detection of papillary thyroid carcinoma by analysis of BRAF and RET/PTC1 mutations in fine-needle aspiration biopsies of thyroid nodules. World J Surg (2010) 0.97
Suspicious ultrasound characteristics predict BRAF V600E-positive papillary thyroid carcinoma. Thyroid (2012) 0.94
Is BRAF mutation associated with lymph node metastasis in patients with papillary thyroid cancer? Surgery (2012) 0.94
Impact of lymph node metastases identified on central neck dissection (CND) on the recurrence of papillary thyroid cancer: potential role of BRAFV600E mutation in defining CND. Endocr Relat Cancer (2013) 0.94
Molecular approaches to thyroid cancer diagnosis. Endocr Relat Cancer (2014) 0.93
BRAFV600E mutation in papillary thyroid microcarcinoma: a meta-analysis. Endocr Relat Cancer (2015) 0.91
Summary statement: utility of molecular marker testing in thyroid cancer. Surgery (2010) 0.90
A prospective study evaluating the accuracy of using combined clinical factors and candidate diagnostic markers to refine the accuracy of thyroid fine needle aspiration biopsy. Surgery (2010) 0.89
Relevance of BRAF(V600E) mutation testing versus RAS point mutations and RET/PTC rearrangements evaluation in the diagnosis of thyroid cancer. Thyroid (2014) 0.87
Associations between BRAF(V600E) and prognostic factors and poor outcomes in papillary thyroid carcinoma: a meta-analysis. World J Surg Oncol (2016) 0.86
Diagnostic and prognostic TERT promoter mutations in thyroid fine-needle aspiration biopsy. Endocr Relat Cancer (2014) 0.85
Cancer: Small papillary thyroid cancers--is BRAF of prognostic value? Nat Rev Endocrinol (2011) 0.85
Three-gene molecular diagnostic model for thyroid cancer. Thyroid (2012) 0.85
Prognostic value of the BRAF V600E mutation in papillary thyroid carcinoma. Oncol Lett (2013) 0.84
The association between BRAF (V600E) mutation and pathological features in PTC. Eur Arch Otorhinolaryngol (2014) 0.84
Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model. Oncotarget (2015) 0.84
Association between single-nucleotide polymorphisms of BRAF and papillary thyroid carcinoma in a Chinese population. Thyroid (2013) 0.83
Molecular markers of aggressiveness of thyroid cancer. Curr Opin Endocrinol Diabetes Obes (2009) 0.83
Surgical implications of B-RafV600E mutation in fine-needle aspiration of thyroid nodules. Am J Surg (2010) 0.82
Translational research in endocrine surgery. Surg Oncol Clin N Am (2013) 0.81
The preeminence of growth pattern and invasiveness and the limited influence of BRAF and RAS mutations in the occurrence of papillary thyroid carcinoma lymph node metastases. Virchows Arch (2011) 0.81
Employing genetic markers to improve diagnosis of thyroid tumor fine needle biopsy. Curr Genomics (2011) 0.80
Molecular diagnostics of fine needle aspiration for the presurgical screening of thyroid nodules. Curr Genomics (2014) 0.80
The prognostic implication and potential role of BRAF mutation in the decision to perform elective neck dissection for thyroid cancer. Gland Surg (2013) 0.78
Intratumoural lymph vessel density is related to presence of lymph node metastases and separates encapsulated from infiltrative papillary thyroid carcinoma. Virchows Arch (2011) 0.78
BRAF mutation correlates with recurrent papillary thyroid carcinoma in Chinese patients. Curr Oncol (2014) 0.78
Clinical significance of preoperative detection of serum p53 antibodies and BRAF(V600E) mutation in patients with papillary thyroid carcinoma. Int J Clin Exp Med (2015) 0.77
BRAF V600E mutation in prognostication of papillary thyroid cancer (PTC) recurrence. Gland Surg (2016) 0.77
Contribution of the BRAF oncogene in the pre-operative phase of thyroid carcinoma. Oncol Lett (2013) 0.77
The Clinicopathological Features of BRAF Mutated Papillary Thyroid Cancers in Chinese Patients. Int J Endocrinol (2015) 0.77
The Risk of Relapse in Papillary Thyroid Cancer (PTC) in the Context of BRAFV600E Mutation Status and Other Prognostic Factors. PLoS One (2015) 0.77
Detection of Circulating BRAF(V600E) in Patients with Papillary Thyroid Carcinoma. J Mol Diagn (2015) 0.77
Molecular targeting of papillary thyroid carcinoma with fluorescently labeled ratiometric activatable cell penetrating peptides in a transgenic murine model. J Surg Oncol (2016) 0.76
Association of BRAF(V600E) Mutation and MicroRNA Expression with Central Lymph Node Metastases in Papillary Thyroid Cancer: A Prospective Study from Four Endocrine Surgery Centers. Thyroid (2016) 0.76
Identification of Intermediate- to High-Risk Papillary Thyroid Carcinoma Patients Who May Be Safely Managed without the Performance of Delayed Stimulated Thyroglobulin Measurements following Total Thyroidectomy and Radioactive Iodine Therapy. Int J Endocrinol (2015) 0.75
Associations of the BRAF(V600E) mutation with sonographic features and clinicopathologic characteristics in a large population with conventional papillary thyroid carcinoma. PLoS One (2014) 0.75
Thyroid function: optimizing molecular testing in thyroid nodule cytology. Nat Rev Endocrinol (2012) 0.75
Well-differentiated thyroid carcinomas: management of the central lymph node compartment and emerging biochemical markers. J Oncol (2011) 0.75
Is BRAF mutation screening useful for preoperative risk stratification in papillary thyroid cancer? Future Oncol (2009) 0.75
RAS Mutations in AUS/FLUS Cytology: Does it Have an Additional Role in BRAFV600E Mutation-Negative Nodules? Medicine (Baltimore) (2015) 0.75
A retrospective study of ultrasound and FNA cytology investigation of thyroid nodules: working towards combined risk stratification. Eur Arch Otorhinolaryngol (2017) 0.75
The utility of the Bethesda category and its association with BRAF mutation in the prediction of papillary thyroid cancer stage. Langenbecks Arch Surg (2017) 0.75
A meta-analysis of prognostic roles of molecular markers in papillary thyroid carcinoma. Endocr Connect (2017) 0.75
Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA (2006) 22.71
Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid (2006) 12.23
High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res (2003) 8.67
Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med (1994) 8.39
A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see commetns]. Cancer (1998) 8.03
BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst (2003) 6.20
BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev (2007) 5.21
Extent of surgery affects survival for papillary thyroid cancer. Ann Surg (2007) 4.73
BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab (2005) 4.39
Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991. Cancer (1997) 3.70
Prospective multicenter study of thyroiscarcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group. Cancer (1998) 3.55
Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid (2006) 3.03
Clinical review 170: A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab (2004) 2.86
Increased incidence of thyroid carcinoma in france: a true epidemic or thyroid nodule management effects? Report from the French Thyroid Cancer Committee. Thyroid (2004) 2.83
The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane. Endocr Relat Cancer (2006) 2.52
Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery (1987) 2.42
The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg (2007) 2.36
Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res (2005) 2.23
Central lymph node dissection in differentiated thyroid cancer. World J Surg (2007) 1.86
BRAF(V600E) mutation and the biology of papillary thyroid cancer. Endocr Relat Cancer (2008) 1.83
Impact of lymph node metastasis in differentiated carcinoma of the thyroid: a matched-pair analysis. Head Neck (1996) 1.82
Value of preoperative ultrasonography in the surgical management of initial and reoperative papillary thyroid cancer. Arch Surg (2006) 1.68
Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population. J Clin Endocrinol Metab (2007) 1.63
Clinical significance of metastasis to the central compartment from papillary microcarcinoma of the thyroid. World J Surg (2006) 1.63
Total thyroidectomy or thyroid lobectomy in patients with low-risk differentiated thyroid cancer: surgical decision analysis of a controversy using a mathematical model. World J Surg (2000) 1.61
Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer. Surgery (2003) 1.60
Risk factors for recurrence to the lymph node in papillary thyroid carcinoma patients without preoperatively detectable lateral node metastasis: validity of prophylactic modified radical neck dissection. World J Surg (2007) 1.58
Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer. J Clin Endocrinol Metab (2004) 1.54
Mutational analysis of BRAF in fine needle aspiration biopsies of the thyroid: a potential application for the preoperative assessment of thyroid nodules. Clin Cancer Res (2004) 1.47
Post-thyroidectomy hypocalcemia. Incidence and risk factors. Am J Surg (1986) 1.41
Complications of neck dissection for thyroid cancer. World J Surg (2002) 1.38
Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry. Thyroid (1998) 1.33
Clinical significance of BRAF (V600E) mutation and Ki-67 labeling index in papillary thyroid carcinomas. Anticancer Res (2007) 1.29
Morbidity of prophylactic lymph node dissection in the central neck area in patients with papillary thyroid carcinoma. Langenbecks Arch Surg (1998) 1.29
Molecular characteristics in papillary thyroid cancers (PTCs) with no 131I uptake. Clin Endocrinol (Oxf) (2007) 1.20
Total thyroidectomy for differentiated thyroid cancer. J Surg Oncol (2006) 1.17
The heterogeneous distribution of BRAF mutation supports the independent clonal origin of distinct tumor foci in multifocal papillary thyroid carcinoma. J Clin Endocrinol Metab (2007) 1.16
Thyroid carcinoma. J Natl Compr Canc Netw (2007) 1.13
BRAF mutation analysis in fine needle aspiration (FNA) cytology of the thyroid. Diagn Mol Pathol (2006) 1.12
Most multifocal papillary thyroid carcinomas acquire genetic and morphotype diversity through subclonal evolution following the intra-glandular spread of the initial neoplastic clone. J Pathol (2008) 1.10
Thyroid reoperations: indications and risks. Am Surg (1998) 1.08
Initial surgical management of thyroid cancer. Surg Oncol Clin N Am (2008) 0.99
Level VI lymph node dissection for papillary thyroid cancer. Minerva Chir (2007) 0.96
Preventable reoperations for persistent and recurrent papillary thyroid carcinoma. Surgery (2004) 0.93
Colorimetric approach to high-throughput mutation analysis. Biotechniques (2005) 0.87
Algorithm for safe and effective reoperative thyroid bed surgery for recurrent/persistent papillary thyroid carcinoma. Head Neck (2007) 0.87
Prognostic factors in thyroid carcinomas. Verh Dtsch Ges Pathol (1997) 0.85
Prognostic factors in well-differentiated thyroid cancer. Rays (2001) 0.84
Routine central neck lymph node dissection for thyroid carcinoma. Surgery (2006) 0.79
Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA (2013) 5.71
Effect of iodine intake on thyroid diseases in China. N Engl J Med (2006) 5.46
BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab (2005) 4.39
Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients. J Clin Oncol (2013) 3.04
Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J Clin Endocrinol Metab (2008) 2.89
The associations of clinicians' implicit attitudes about race with medical visit communication and patient ratings of interpersonal care. Am J Public Health (2012) 2.49
Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring. Clin Infect Dis (2006) 2.06
Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11. Neuro Oncol (2004) 2.03
Severe prolonged sedation associated with coadministration of protease inhibitors and intravenous midazolam during bronchoscopy. Pharmacotherapy (2012) 2.01
BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis. Medicine (Baltimore) (2012) 1.77
Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244. J Clin Endocrinol Metab (2007) 1.66
Long-term corticosteroid replacement and bone mineral density in adult women with classical congenital adrenal hyperplasia. J Clin Endocrinol Metab (2005) 1.63
Is routine dissection of level II-B and V-A necessary in patients with papillary thyroid cancer undergoing lateral neck dissection for FNA-confirmed metastases in other levels. World J Surg (2009) 1.59
Molecular classification of thyroid nodules using high-dimensionality genomic data. J Clin Endocrinol Metab (2010) 1.57
Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer. Int J Cancer (2006) 1.56
A randomized trial to improve patient-centered care and hypertension control in underserved primary care patients. J Gen Intern Med (2011) 1.55
Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer. J Clin Endocrinol Metab (2009) 1.55
TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer. J Clin Endocrinol Metab (2014) 1.52
High prevalence and mutual exclusivity of genetic alterations in the phosphatidylinositol-3-kinase/akt pathway in thyroid tumors. J Clin Endocrinol Metab (2007) 1.47
A randomized controlled trial of interventions to enhance patient-physician partnership, patient adherence and high blood pressure control among ethnic minorities and poor persons: study protocol NCT00123045. Implement Sci (2009) 1.46
Diffusion tensor imaging of the brainstem in children with achondroplasia. Dev Med Child Neurol (2014) 1.43
Highly frequent PIK3CA amplification is associated with poor prognosis in gastric cancer. BMC Cancer (2012) 1.39
Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3-kinase/AKT signaling pathway in thyroid tumors. Cancer (2008) 1.39
Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review. Gynecol Oncol (2012) 1.38
Vivo motion and force measurement of surgical needle intervention during prostate brachytherapy. Med Phys (2006) 1.36
Upper airway dynamic responses in children with the obstructive sleep apnea syndrome. Pediatr Res (2004) 1.35
Perceived susceptibility to chronic kidney disease among high-risk patients seen in primary care practices. J Gen Intern Med (2009) 1.31
Isolation and identification of bifidobacteriaceae from human saliva. Appl Environ Microbiol (2008) 1.31
Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial. J Clin Oncol (2007) 1.31
Developmental changes in upper airway dynamics. J Appl Physiol (1985) (2004) 1.30
Emended description of Actinomyces naeslundii and descriptions of Actinomyces oris sp. nov. and Actinomyces johnsonii sp. nov., previously identified as Actinomyces naeslundii genospecies 1, 2 and WVA 963. Int J Syst Evol Microbiol (2009) 1.29
Effect of platelet rich plasma and fibrin sealant on facial nerve regeneration in a rat model. Laryngoscope (2007) 1.27
A diagnostic predictor model for indeterminate or suspicious thyroid FNA samples. Thyroid (2008) 1.27
Immunodeficiency and infections in ataxia-telangiectasia. J Pediatr (2004) 1.26
Population structure of Streptococcus oralis. Microbiology (2009) 1.25
In silico pharmacogenetics of warfarin metabolism. Nat Biotechnol (2006) 1.25
A prospective study of protein excretion using short-interval timed urine collections in patients with lupus nephritis. Kidney Int (2009) 1.24
Provider and clinic cultural competence in a primary care setting. Soc Sci Med (2007) 1.23
Highly frequent promoter methylation and PIK3CA amplification in non-small cell lung cancer (NSCLC). BMC Cancer (2011) 1.19
Night-to-night variability of polysomnography in children with suspected obstructive sleep apnea. J Pediatr (2002) 1.18
Phase 2 trial of copper depletion and penicillamine as antiangiogenesis therapy of glioblastoma. Neuro Oncol (2005) 1.16
Antithyroperoxidase and antithyroglobulin antibodies in a five-year follow-up survey of populations with different iodine intakes. J Clin Endocrinol Metab (2008) 1.16
Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: a dose escalation and pharmacologic study. Neuro Oncol (2005) 1.16
The effect of patient race and blood pressure control on patient-physician communication. J Gen Intern Med (2009) 1.15
Long-term pain and activity during recovery from major thoracotomy using thoracic epidural analgesia. Anesthesiology (2002) 1.12
The role of positron emission tomography/computed tomography in the management of recurrent papillary thyroid carcinoma. Laryngoscope (2005) 1.12
Thyroid hormone analogs for treatment of hypercholesterolemia and heart failure: past, present and future prospects. J Mol Cell Cardiol (2004) 1.11
The impact of health literacy on desire for participation in healthcare, medical visit communication, and patient reported outcomes among patients with hypertension. J Gen Intern Med (2013) 1.10
Prognostic significance of aberrant gene methylation in gastric cancer. Am J Cancer Res (2011) 1.10
Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma. J Neurooncol (2010) 1.10
Long-term outcome in PCNSL patients treated with high-dose methotrexate and deferred radiation. Neurology (2008) 1.08
Brain magnetic resonance imaging in newly diagnosed systemic lupus erythematosus. J Rheumatol (2008) 1.07
Antidiabetic drugs and heart failure risk in patients with type 2 diabetes in the U.K. primary care setting. Diabetes Care (2005) 1.07
MiR-145 inhibits oral squamous cell carcinoma (OSCC) cell growth by targeting c-Myc and Cdk6. Cancer Cell Int (2013) 1.05
Creating a transdisciplinary research center to reduce cardiovascular health disparities in Baltimore, Maryland: lessons learned. Am J Public Health (2013) 1.04
Cognitive outcome in adult women affected by congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Horm Res (2006) 1.04
Stereotactic radiosurgery in the management of brain metastases: an institutional retrospective analysis of survival. Int J Radiat Oncol Biol Phys (2009) 1.04
A multi-level system quality improvement intervention to reduce racial disparities in hypertension care and control: study protocol. Implement Sci (2013) 1.03
Recombinant human thyrotropin stimulation of fluoro-D-glucose positron emission tomography uptake in well-differentiated thyroid carcinoma. J Clin Endocrinol Metab (2004) 1.02
Frequent gene amplification predicts poor prognosis in gastric cancer. Int J Mol Sci (2012) 1.00
Generation of diversity in Streptococcus mutans genes demonstrated by MLST. PLoS One (2010) 1.00
Efficacy and toxicity of the antisense oligonucleotide aprinocarsen directed against protein kinase C-alpha delivered as a 21-day continuous intravenous infusion in patients with recurrent high-grade astrocytomas. Neuro Oncol (2005) 0.99
Depression and cognitive impairment in newly diagnosed systemic lupus erythematosus. J Rheumatol (2010) 0.99
Results of penetrating keratoplasty performed with a femtosecond laser zigzag incision initial report. Ophthalmology (2007) 0.98
Human hepatocellular carcinoma in a mouse model: assessment of tumor response to percutaneous ablation by using glyceraldehyde-3-phosphate dehydrogenase antagonists. Radiology (2012) 0.98
Decreased 5-hydroxymethylcytosine (5-hmC) is an independent poor prognostic factor in gastric cancer patients. J Biomed Nanotechnol (2013) 0.97
Physician cultural competence and patient ratings of the patient-physician relationship. J Gen Intern Med (2009) 0.97
Initial response to glucocorticoids. Cancer (2006) 0.95
Dual inhibition of RET and FGFR4 restrains medullary thyroid cancer cell growth. Clin Cancer Res (2005) 0.95
Elevated serum IL-8 levels in ataxia telangiectasia. J Pediatr (2010) 0.95
Quantitative analysis of promoter hypermethylation in multiple genes in osteosarcoma. Cancer (2006) 0.94
Quantitative assessment of gene methylation and their impact on clinical outcome in gastric cancer. Clin Chim Acta (2012) 0.94
Cognitive function in a systemic lupus erythematosus inception cohort. J Rheumatol (2008) 0.94
EGFR and KRAS mutations in metastatic lung adenocarcinomas. Hum Pathol (2011) 0.93
Physician communication behaviors and trust among black and white patients with hypertension. Med Care (2013) 0.93
Estrogen Induces Metastatic Potential of Papillary Thyroid Cancer Cells through Estrogen Receptor α and β. Int J Endocrinol (2013) 0.93
Participation and crowd out: assessing the effects of parental Medicaid expansions. J Health Econ (2012) 0.92
A microarray to analyze methylation patterns of p16(Ink4a) gene 5'-CpG islands. Clin Biochem (2003) 0.92
The incidence of central neck micrometastatic disease in patients with papillary thyroid cancer staged preoperatively and intraoperatively as N0. Surgery (2011) 0.92
The effect of enzyme-inducing antiseizure drugs on the pharmacokinetics and tolerability of procarbazine hydrochloride. Clin Cancer Res (2006) 0.92
Lack of mutations in the thyroid hormone receptor (TR) alpha and beta genes but frequent hypermethylation of the TRbeta gene in differentiated thyroid tumors. J Clin Endocrinol Metab (2007) 0.92
Impact of fluconazole prophylaxis on cortisol levels in critically ill surgical patients. Antimicrob Agents Chemother (2004) 0.92
Physician burnout and patient-physician communication during primary care encounters. J Gen Intern Med (2008) 0.92
Defining the risk of involvement for each neck nodal level in patients with early T-stage node-positive oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys (2009) 0.92
Evidence for recombination between a sialidase (nanH) of Actinomyces naeslundii and Actinomyces oris, previously named 'Actinomyces naeslundii genospecies 1 and 2'. FEMS Microbiol Lett (2008) 0.92
Correlation between BRAF mutation and promoter methylation of TIMP3, RARβ2 and RASSF1A in thyroid cancer. Epigenetics (2012) 0.90
Stereotactic radiosurgery and hypofractionated stereotactic radiotherapy: normal tissue dose constraints of the central nervous system. Cancer Treat Rev (2011) 0.90
Patient trust in physicians and adoption of lifestyle behaviors to control high blood pressure. Patient Educ Couns (2012) 0.90
Hypermethylation of the DNA mismatch repair gene hMLH1 and its association with lymph node metastasis and T1799A BRAF mutation in patients with papillary thyroid cancer. Cancer (2008) 0.90
Survival implications of cervical lymphadenectomy in patients with medullary thyroid cancer. Ann Surg Oncol (2010) 0.90
Phase II clinical and pharmacologic study of radiation therapy and carboxyamido-triazole (CAI) in adults with newly diagnosed glioblastoma multiforme. Invest New Drugs (2006) 0.89
Suramin and radiotherapy in newly diagnosed glioblastoma: phase 2 NABTT CNS Consortium study. Neuro Oncol (2004) 0.89
TERT promoter mutations predict worse survival in laryngeal cancer patients. Int J Cancer (2014) 0.89
Metallothionein 1G functions as a tumor suppressor in thyroid cancer through modulating the PI3K/Akt signaling pathway. BMC Cancer (2013) 0.89
Induction of thyroid gene expression and radioiodine uptake in melanoma cells: novel therapeutic implications. PLoS One (2009) 0.89
Management of recurrent and persistent metastatic lymph nodes in well-differentiated thyroid cancer: a multifactorial decision-making guide for the thyroid cancer care collaborative. Head Neck (2014) 0.88
Usefulness of serum thyrotropin for risk prediction of differentiated thyroid cancers does not apply to microcarcinomas: results of 1,870 Chinese patients with thyroid nodules. Endocr J (2012) 0.88
High outpatient pain intensity scores predict impending hospital admissions in patients with cancer. J Pain Symptom Manage (2009) 0.88